JPH0244759Y2 - - Google Patents
Info
- Publication number
- JPH0244759Y2 JPH0244759Y2 JP1985184524U JP18452485U JPH0244759Y2 JP H0244759 Y2 JPH0244759 Y2 JP H0244759Y2 JP 1985184524 U JP1985184524 U JP 1985184524U JP 18452485 U JP18452485 U JP 18452485U JP H0244759 Y2 JPH0244759 Y2 JP H0244759Y2
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- blood
- pump
- separator
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004369 blood Anatomy 0.000 claims description 44
- 239000008280 blood Substances 0.000 claims description 44
- 239000012530 fluid Substances 0.000 claims description 14
- 230000017531 blood circulation Effects 0.000 claims description 13
- 210000000601 blood cell Anatomy 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000012510 hollow fiber Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Description
【考案の詳細な説明】
〔産業上の利用分野〕
この考案は、血液から血球成分と血漿成分を分
離する血漿分離器と、分離した血漿からその高分
子量成分を除去する血漿成分分離器とを有する血
液の体外処理装置に関するものである。[Detailed description of the invention] [Industrial application field] This invention consists of a plasma separator that separates blood cell components and plasma components from blood, and a plasma component separator that removes high molecular weight components from the separated plasma. The present invention relates to an extracorporeal blood processing device having the following methods.
腎不全、肝不全、自己免疫疾患等の治療法とし
て、二重ろ過型血漿分離交換方法が知られている
（特公昭60−40302号公報）。
A double filtration type plasma separation and exchange method is known as a treatment for renal failure, liver failure, autoimmune diseases, etc. (Japanese Patent Publication No. 40302/1983).
上記治療方法を行う血液処理装置では、血漿分
離器に収容した膜に目詰りが発生したり、返血不
良に陥つた場合等には血漿分離器への血液の導入
が困難になる。 In a blood processing apparatus that performs the above-mentioned treatment method, it becomes difficult to introduce blood into the plasma separator if the membrane housed in the plasma separator becomes clogged or there is insufficient blood return.
しかし、血漿分離器の上流に設けられたポンプ
により血漿分離器へは一定流量の血液が送給され
るため大きな入口側圧力が加わり血球を破壊させ
るおそれがある。 However, since a constant flow rate of blood is fed to the plasma separator by a pump provided upstream of the plasma separator, a large pressure on the inlet side may be applied, which may destroy blood cells.
そこで従来は血漿分離器の入口側に圧力検知器
を設け、この圧力計が設定値を超えた場合、全て
のポンプを停止させる方法がとられている。 Conventionally, therefore, a pressure sensor is provided on the inlet side of the plasma separator, and when this pressure sensor exceeds a set value, all pumps are stopped.
ところが、ポンプを停止させた場合、血液循環
流路内の血液の流れが止まり、血液が凝固する恐
れがある。また、圧力が所定の設定値以内に回復
すると、そのつど手動でスタート信号を送つて、
ポンプを再始動させるなど、操作が面倒である。
However, when the pump is stopped, the flow of blood in the blood circulation channel is stopped, and there is a risk that the blood may coagulate. Also, each time the pressure recovers to within a predetermined set value, a start signal is sent manually.
Operations such as restarting the pump are cumbersome.
この考案は、上記従来の問題を解消するために
なされたもので、血漿分離器の入口側圧力が設定
値を超えた時、第１および第２のポンプ回転数を
低下させて、血漿分離器への入口圧力の増大を抑
制し、入口側圧力が設定値以内に回復後、第１お
よび第２のポンプの回転数を所定の値まで自動的
に復帰させることを目的とする。 This invention was made in order to solve the above-mentioned conventional problem. When the pressure on the inlet side of the plasma separator exceeds a set value, the rotational speed of the first and second pumps is lowered, and the plasma separator The purpose of the present invention is to suppress an increase in the inlet pressure to the pump and automatically restore the rotational speed of the first and second pumps to a predetermined value after the inlet pressure recovers to within a set value.
上記目的を達成するためのこの考案の構成を第
１図に示す。
The structure of this invention for achieving the above object is shown in FIG.
血液循環流路１は、血液導入部Ｈ１から取り出
された血液を血球成分と血漿成分とに分離する血
漿分離器３と、第１のポンプ装置４とを備え、分
離された血球成分を、血漿分離器３の下流の血液
循環流路を経て、血液導出部Ｈ２より患者の体内
へ戻す。また、血液循環流路における第１のポン
プ装置４と血漿分離器３との間には入口圧力を検
知する圧力検知器２３が設けられている。 The blood circulation channel 1 includes a plasma separator 3 that separates the blood taken out from the blood introduction part H1 into blood cell components and plasma components, and a first pump device 4, and converts the separated blood cell components into plasma. The blood passes through the blood circulation channel downstream of the separator 3 and is returned to the patient's body from the blood outlet H2. Further, a pressure detector 23 is provided between the first pump device 4 and the plasma separator 3 in the blood circulation channel to detect the inlet pressure.
血漿流路２は、上記血漿分離器３で分離された
血漿成分を高分子量成分と低分子量成分とに分離
する血漿成分分離器６と、第２のポンプ装置７
と、補液供給源１２とを備え、分離された低分子
量成分を、上記血液循環流路１を経て患者の体内
へ戻す。一方高分子量成分はドレン開口Ｄから外
部へ排出し、上記補液供給源１２から補液を血漿
成分分離器６に供給し、低分子量成分に混合す
る。 The plasma flow path 2 includes a plasma component separator 6 that separates the plasma components separated by the plasma separator 3 into high molecular weight components and low molecular weight components, and a second pump device 7.
and a replacement fluid supply source 12, and the separated low molecular weight components are returned to the patient's body via the blood circulation channel 1. On the other hand, the high molecular weight components are discharged to the outside from the drain opening D, and the replacement fluid is supplied from the replacement fluid supply source 12 to the plasma component separator 6, where it is mixed with the low molecular weight components.
１３はポンプ駆動手段であり、上記第１のポン
プ装置４および第２のポンプ装置７を所定の流量
比になるように常速で駆動する。１４は低速駆動
手段であり、常時は作動しないで、上記圧力検知
器の圧力が所定の値を超えた時、上記第１および
第２のポンプ装置４，７の回転数を低下させ、か
つ上記所定の流量比になるように駆動する。 Reference numeral 13 denotes a pump driving means, which drives the first pump device 4 and the second pump device 7 at normal speed so as to maintain a predetermined flow rate ratio. Reference numeral 14 denotes a low-speed drive means, which is not normally operated, and when the pressure of the pressure detector exceeds a predetermined value, reduces the rotational speed of the first and second pump devices 4, 7, and Drive to achieve a predetermined flow rate ratio.
上記構成において、常時は、低速駆動手段１４
が作動しないで、ポンプ駆動手段１３が第１のポ
ンプ装置４、第２のポンプ装置７を予め設定され
た所定の流量比となるように常速で駆動し、血液
導入部Ｈ１から取り出された患者の血液を、血漿
分離器３および血漿成分分離器６で分離したの
ち、血球成分と、補液が混入された低分子量成分
とを、血液導出部Ｈ２から患者の体内へ戻す。上
記所定の流量比は、患者の病状や体質に応じてろ
過を円滑に行なうために、予め定められているも
のである。
In the above configuration, the low speed drive means 14
is not activated, the pump driving means 13 drives the first pump device 4 and the second pump device 7 at a normal speed so that a predetermined flow rate ratio is achieved, and the blood is taken out from the blood introduction part H1. After the patient's blood is separated by the plasma separator 3 and the plasma component separator 6, blood cell components and low molecular weight components mixed with replacement fluid are returned to the patient's body from the blood outlet H2. The predetermined flow rate ratio is predetermined in order to smoothly perform filtration according to the patient's medical condition and constitution.
処理中に血漿分離器に目詰りが生じた場合、ま
た返血不良に陥つた場合等には、第１および第２
のポンプの回転数を低下させ、血漿分離器へ過大
の圧力が加わることを抑制し、入口側圧力が設定
値以内に回復後は、上記第１および第２のポンプ
装置４，７を所定の流量に復帰させる。 If the plasma separator becomes clogged during processing or if there is a problem with blood return, the first and second
After the inlet side pressure has recovered to within the set value, the first and second pump devices 4 and 7 are operated at a predetermined level. Return to flow rate.
このように、血漿分離器の入口側圧力の異常の
際にもポンプ装置を停止させることなく低速で駆
動させるから、異常圧力解消後は手動でスタート
を送つてポンプ装置を再始動させる必要がない。
また流路内に常時血液を流すため血液が凝固する
ことはない。しかも各ポンプは低流量時でも所定
の連動比で駆動されるため血液の処理は低速なが
ら円滑に行われる。 In this way, even when the pressure on the inlet side of the plasma separator is abnormal, the pump device is driven at low speed without stopping, so there is no need to manually send a start signal to restart the pump device after the abnormal pressure is resolved. .
Furthermore, since blood is constantly flowing through the flow path, blood does not coagulate. Moreover, since each pump is driven at a predetermined interlocking ratio even when the flow rate is low, blood processing is performed smoothly at low speed.
以下、この考案の実施例を図面にしたがつて説
明する。
Embodiments of this invention will be described below with reference to the drawings.
第２図において、１は血液循環流路、２は血漿
流路である。血液導入部Ｈ１（シヤント、注射針
などの通常の採血器や貯血器などと連絡できる部
分）から取り出された患者の血液は、第１のポン
プ装置を構成する血液ポンプ４により昇圧されて
て動脈圧チヤンバ１６に入り、ついで、血漿分離
器３にその上側から導入され、血球成分と血漿成
分とに分離される。この血漿分離器３には、血漿
分離膜、たとえばポリビニルアルコール（PVA）
系の共重合体などからなる平板状、チユーブ状、
または中空糸状の分離膜が収容されている。通常
は、中空糸状の分離膜を多数寄せ集めたものが用
いられる。 In FIG. 2, 1 is a blood circulation channel, and 2 is a plasma channel. The patient's blood taken out from the blood introduction part H1 (the part that can communicate with a normal blood collection device such as a shunt or a syringe needle or a blood storage device) is pressurized by the blood pump 4 constituting the first pump device and then transferred to the artery. The blood enters the pressure chamber 16 and is then introduced into the plasma separator 3 from above, where it is separated into blood cell components and plasma components. This plasma separator 3 includes a plasma separation membrane, such as polyvinyl alcohol (PVA).
flat, tube-shaped,
Alternatively, a hollow fiber separation membrane is housed. Usually, a collection of a large number of hollow fiber separation membranes is used.
上記血漿分離器３で分離された血球成分は、静
脈圧チヤンバ１８に入り、気泡検知器１９を経て
血液導出部Ｈ２（シヤントや点滴セツトなどに連
結できる部分）から患者の体内へ戻る。 The blood cell components separated by the plasma separator 3 enter the venous pressure chamber 18, pass through the air bubble detector 19, and return to the patient's body from the blood outlet H2 (a part that can be connected to a shunt, drip set, etc.).
さらに、上記血液ポンプ４の上流側には、流路
の陰圧を検知するピロースイツチ２１が設けられ
ている。 Further, on the upstream side of the blood pump 4, a pillow switch 21 is provided to detect negative pressure in the flow path.
また、上記動脈圧チヤンバ１６には、血液中に
ヘパリンを少量だけ混入させて、処理中の血液の
凝固を防止するヘパリン注入器２２と、動脈圧セ
ンサ２３とが接続され、上記血漿分離器３には、
ろ過圧センサ２４が接続され、上記静脈圧チヤン
バ１８には、静脈圧センサ２６が接続されてい
る。 Also, connected to the arterial pressure chamber 16 are a heparin injector 22 that mixes a small amount of heparin into blood to prevent blood from coagulating during treatment, and an arterial pressure sensor 23. for,
A filtration pressure sensor 24 is connected, and a venous pressure sensor 26 is connected to the venous pressure chamber 18.
上記血漿分離器３で分離された血漿成分は、血
漿流路２の血漿ポンプ７１により昇圧されて２次
膜圧チヤンバ３２に入り、血漿成分分離器６にそ
の下側から導入されて、高分子量成分と低分子量
成分とに分離される。この血漿成分分離器６に
は、血漿処理膜、たとえばエチレンビニルアルコ
ール（EVA）系の共重合体などからなる平板状、
チユーブ状、または中空糸状の分離膜が収容され
ている。通常は、中空糸状の分離膜を多数寄せ集
めたものが用いられる。 The plasma components separated by the plasma separator 3 are pressurized by the plasma pump 71 in the plasma flow path 2, enter the secondary membrane pressure chamber 32, and are introduced into the plasma component separator 6 from below, where they are high molecular weight. components and low molecular weight components. The plasma component separator 6 includes a plasma processing membrane, such as a flat plate made of an ethylene vinyl alcohol (EVA) copolymer, etc.
A tube-shaped or hollow fiber-shaped separation membrane is accommodated. Usually, a collection of a large number of hollow fiber separation membranes is used.
上記血漿成分分離器６で分離された高分子量成
分は、ドレンポンプ７２により、血漿成分分離器
６の上方からドレン開口Ｄを経て外部へ排出され
る。一方、低分子量成分は、血漿成分分離器６よ
りも下流側の血漿流路２から、血液循環流路１の
血漿分離器３よりも下流側の流路を経て人体へ戻
される。上記血漿ポンプ７１とドレンポンプ７２
とが第２のポンプ装置７を構成する。 The high molecular weight components separated by the plasma component separator 6 are discharged from above the plasma component separator 6 to the outside through the drain opening D by the drain pump 72. On the other hand, the low molecular weight components are returned to the human body from the plasma channel 2 downstream of the plasma component separator 6 through the channel downstream of the plasma separator 3 in the blood circulation channel 1. The plasma pump 71 and drain pump 72
constitutes the second pump device 7.
上記２次膜圧チヤンバ３２には、２次膜圧セン
サ３７が接続され、上記血漿成分分離器６には、
上記ドレンポンプ７２および気泡検知器４０を介
して、補液導入部Ｈ３（点滴セツトなどに連結で
きる部分）が、アルブミンやHES等の補液を供
給する補液供給源１２に接続され、補液が上記ド
レンポンプ７２により血漿成分分離器６内へ送ら
れて、低分子量成分に混入される。 A secondary membrane pressure sensor 37 is connected to the secondary membrane pressure chamber 32, and the plasma component separator 6 includes:
Via the drain pump 72 and the bubble detector 40, the replacement fluid introduction part H3 (a part that can be connected to an intravenous drip set, etc.) is connected to the replacement fluid supply source 12 that supplies replacement fluid such as albumin or HES, and the replacement fluid is supplied to the drain pump. 72 into the plasma component separator 6 where it is mixed with low molecular weight components.
ここで、上記ドレンポンプ７２は高分子量成分
の排出と補液の供給とを兼ねているが、これとは
異なり、高分子量成分の排出と、補液の供給とを
別個のポンプで行なうようにしてもよい。ただ
し、この実施例のように、兼用構成とすれば、特
に制御しなくても、高分子量成分の排出量と、補
液の供給量とが常に等しくなるので、好都合であ
る。 Here, the drain pump 72 serves both to discharge high molecular weight components and to supply replacement fluid, but unlike this, it is also possible to use separate pumps to discharge high molecular weight components and supply replacement fluid. good. However, if a dual-use structure is adopted as in this embodiment, the discharge amount of the high molecular weight component and the supply amount of the replacement fluid are always equal to each other without any particular control, which is advantageous.
さらに、上記血液ポンプ４には、この血液ポン
プ４の回転数に基づいて血液循環流路１の流量を
検知する血液量検知器８０が、上記血漿ポンプ７
１には、この血漿ポンプ７１の回転数に基づいて
血漿流路２の流量を検知する血漿量検知器８１
が、上記ドレンポンプ７２には、このドレンポン
プ７２の回転数に基づいてドレン量を検知するド
レン量検知器８２が、それぞれ接続されている。 Further, the blood pump 4 includes a blood volume detector 80 that detects the flow rate of the blood circulation channel 1 based on the rotation speed of the blood pump 4.
1 includes a plasma volume detector 81 that detects the flow rate of the plasma flow path 2 based on the rotation speed of the plasma pump 71.
However, each of the drain pumps 72 is connected to a drain amount detector 82 that detects the amount of drain based on the rotation speed of the drain pump 72.
４８はマイクロコンピユータからなる制御装置
で、第１図のポンプ駆動手段１３および低速駆動
手段１４を内蔵している。 Reference numeral 48 denotes a control device consisting of a microcomputer, which incorporates the pump driving means 13 and low-speed driving means 14 shown in FIG.
上記構成において、患者の治療にあたつて、ま
ず、血液導入部Ｈ１と血液導出部Ｈ２を患者の血
管に差し込み、外部からのスタート指令により、
上記各ポンプ４，７１，７２を回転させる。 In the above configuration, when treating a patient, first, the blood introduction part H1 and the blood extraction part H2 are inserted into the patient's blood vessel, and in response to an external start command,
Each of the pumps 4, 71, 72 is rotated.
ここで、臨床運転時には、上記制御装置４８の
ポンプ駆動手段１３により、上記各ポンプ４，７
７，７２を予め設定された常速で駆動し、上記各
検知器８０，８１，８２からの流量検知信号と、
各圧力センサからの２３，２４，２６，３７から
の圧力検知信号とを受けて、血漿分離器３内と血
漿成分分離器６内の膜圧が適正範囲内にあること
を確認しながら、各ポンプ４，７１，７２の流量
比が所定値、たとえば10：３：１になるように、
上記各ポンプ４，７１，７２の回転数を微調整す
る。こうして、血液導入部Ｈ１から取り出された
患者の血液を、血漿分離器３および血漿成分分離
器６で分離したのち、血球成分と補液が混合され
た低分子量成分とを、血液導出部Ｈ２から患者の
体内へ戻す。上記所定の流量比は、患者の病状や
体質に応じて円滑にろ過するために、予め定めら
れており、必要に応じて、外部からの入力操作に
より変更される。 Here, during clinical operation, each of the pumps 4 and 7 is controlled by the pump driving means 13 of the control device 48.
7, 72 are driven at a preset normal speed, and the flow rate detection signals from the respective detectors 80, 81, 82 are detected.
After receiving the pressure detection signals from each pressure sensor 23, 24, 26, and 37, each so that the flow rate ratio of the pumps 4, 71, and 72 is a predetermined value, for example, 10:3:1.
The rotational speed of each of the pumps 4, 71, 72 is finely adjusted. In this way, the patient's blood taken out from the blood introduction part H1 is separated by the plasma separator 3 and the plasma component separator 6, and then the low molecular weight component, which is a mixture of blood cell components and replacement fluid, is delivered to the patient from the blood delivery part H2. return to the body. The above-described predetermined flow rate ratio is predetermined in order to ensure smooth filtration according to the patient's medical condition and constitution, and can be changed by external input operation as necessary.
治療中圧力検知器２３は、血液循環流路におけ
る第１のポンプ装置４と血漿分離器３との間、す
なわち血漿分離器の入口側の圧力を、常に検知し
ている。そして血漿分離器に目詰りが発生した
り、返血不良になつて、入口側圧力が上昇し、こ
の圧力が設定値を超えると検知信号を発信する。
この検知信号を受けて制御装置４８の低速駆動手
段１４が作動し、上記各ポンプ４，７１，７２の
回転を所定の連動比を保ちながら低下させ、血漿
分離器への圧力の増大を抑制する。血漿分離器の
入口側圧力が設定値以下に回復したとき、制御装
置４８の低速駆動手段１４が不作動になつて、ポ
ンプ駆動手段１３によつて各ポンプ４，７１，７
２を所定の速度で駆動させる。 The pressure detector 23 during treatment constantly detects the pressure between the first pump device 4 and the plasma separator 3 in the blood circulation channel, that is, on the inlet side of the plasma separator. If the plasma separator becomes clogged or blood is not returned properly, the pressure on the inlet side increases, and if this pressure exceeds a set value, a detection signal is sent.
In response to this detection signal, the low-speed drive means 14 of the control device 48 is activated to reduce the rotation of each of the pumps 4, 71, 72 while maintaining a predetermined interlocking ratio, thereby suppressing an increase in pressure to the plasma separator. . When the pressure on the inlet side of the plasma separator recovers below the set value, the low-speed drive means 14 of the control device 48 becomes inactive, and the pump drive means 13 controls the pumps 4, 71, 7.
2 at a predetermined speed.
このように、血漿分離器の入口圧力が設定値を
超えたとき、ポンプの回転を低下させ、設定値以
内に回復後、所定の流量まで復帰させるため、血
液凝固の原因となるポンプ停止の事態を避けるこ
とができる。しかもポンプ４，７１，７２は低流
量時でも、所定の連動比は確保される。 In this way, when the inlet pressure of the plasma separator exceeds the set value, the rotation of the pump is reduced, and after it recovers to within the set value, it returns to the specified flow rate, which prevents the pump from stopping, which may cause blood clotting. can be avoided. Moreover, even when the pumps 4, 71, and 72 have low flow rates, a predetermined interlock ratio is ensured.
以上説明したように、この考案によれば、血漿
分離器の入口側圧力が設定値を超えたとき、第１
のポンプ装置４および第２のポンプ装置７の回転
数が低下させるため血漿分離器への過圧を防ぎ、
また設定値以内に回復すると所定の流量まで復帰
するため、血液凝固の原因になるポンプ停止の事
態を避けることができる。
As explained above, according to this invention, when the pressure on the inlet side of the plasma separator exceeds the set value, the first
The rotational speed of the pump device 4 and the second pump device 7 is reduced to prevent overpressure to the plasma separator.
In addition, when the flow rate is restored to within the set value, the flow rate returns to the predetermined flow rate, so it is possible to avoid a situation in which the pump stops, which may cause blood coagulation.
しかも、第１のポンプ装置４および第２のポン
プ装置７は、低速状態でも所定の流量比が確保さ
れているから、血液のろ過は低速ながら円滑に行
なわれる。 Furthermore, since the first pump device 4 and the second pump device 7 maintain a predetermined flow rate ratio even in a low speed state, blood filtration is performed smoothly even at a low speed.
第１図はこの考案の構成を示す回路図、第２図
はこの考案の一実施例を示す二重ろ過型血液処理
装置の回路図である。
１……血液循環流路、２……血漿流路、３……
血漿分離器、４……第１のポンプ装置、６……血
漿成分分離器、７……第２のポンプ装置、１２…
…補液供給源、１３……ポンプ駆動手段、１４…
…低速駆動手段、２３……圧力検知器。
FIG. 1 is a circuit diagram showing the configuration of this invention, and FIG. 2 is a circuit diagram of a double filtration type blood processing apparatus showing one embodiment of this invention. 1... Blood circulation channel, 2... Plasma channel, 3...
Plasma separator, 4... first pump device, 6... plasma component separator, 7... second pump device, 12...
... Replacement fluid supply source, 13... Pump driving means, 14...
...Low speed drive means, 23...Pressure detector.
Claims (1)
入して、血球成分と血漿成分とに分離し、分離さ
れた血球成分を血液導出部Ｈ２より人体へ戻す血
液循環流路１と、 上記血漿分離器３で分離された血漿成分を、血
漿成分分離器６に導入して高分子量成分と低分子
量成分とに分離し、分離された低分子量成分に補
液を加えた後、上記血液循環流路１を経て人体へ
戻す血漿流路２と、 上記血液循環流路１に設けられた第１のポンプ
装置４と、 上記血漿流路２に設けられた第２のポンプ装置
７と、 上記血液循環流路１における第１のポンプ装置
４と血漿分離器３との間の圧力を検知する圧力検
出器２３と、 上記第１および第２のポンプ装置４，７を所定
の流量比になるように常速で駆動するポンプ駆動
手段１３と、 上記圧力検出器２３からの異常圧力検知信号を
受けて作動し、上記第１および第２のポンプ装置
４，７を常速よりも遅い低速で、かつ上記所定の
流量比になるように駆動する低速駆動手段１４と
を備えてなる血液の体外処理装置。[Scope of Claim for Utility Model Registration] Blood is introduced into the plasma separator 3 from the blood introduction part H1, separated into blood cell components and plasma components, and the separated blood cell components are returned to the human body from the blood delivery part H2. The plasma components separated by the circulation channel 1 and the plasma separator 3 are introduced into the plasma component separator 6 to be separated into high molecular weight components and low molecular weight components, and a replacement fluid is added to the separated low molecular weight components. After that, a plasma flow path 2 is returned to the human body via the blood circulation flow path 1, a first pump device 4 provided in the blood circulation flow path 1, and a second pump device provided in the plasma flow path 2. a pump device 7; a pressure detector 23 that detects the pressure between the first pump device 4 and the plasma separator 3 in the blood circulation channel 1; A pump driving means 13 is driven at a normal speed to maintain a predetermined flow rate ratio, and a pump driving means 13 is operated in response to an abnormal pressure detection signal from the pressure detector 23 to constantly drive the first and second pump devices 4 and 7. and a low-speed drive means 14 that is driven at a low speed that is slower than the above-described flow rate and at the predetermined flow rate ratio.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1985184524U JPH0244759Y2 (en) | 1985-11-29 | 1985-11-29 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1985184524U JPH0244759Y2 (en) | 1985-11-29 | 1985-11-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6292836U JPS6292836U (en) | 1987-06-13 |
| JPH0244759Y2 true JPH0244759Y2 (en) | 1990-11-28 |
Family
ID=31132282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1985184524U Expired JPH0244759Y2 (en) | 1985-11-29 | 1985-11-29 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0244759Y2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314624A (en) * | 1991-03-26 | 1994-05-24 | Otsuka Pharmaceutical Factory, Inc. | Process for filtering plasma and regenerating a secondary filter therefor |
| WO2016039153A1 (en) * | 2014-09-12 | 2016-03-17 | 憲一郎 押川 | Binding tool for binder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62137061A (en) * | 1985-11-07 | 1987-06-19 | 株式会社クラレ | Double filtering type blood treatment apparatus |
-
1985
- 1985-11-29 JP JP1985184524U patent/JPH0244759Y2/ja not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62137061A (en) * | 1985-11-07 | 1987-06-19 | 株式会社クラレ | Double filtering type blood treatment apparatus |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6292836U (en) | 1987-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4828543A (en) | Extracorporeal circulation apparatus | |
| US4747952A (en) | Method and apparatus for plasma treatment | |
| JPS583705B2 (en) | Double filtration plasma exchange device | |
| JP4101512B2 (en) | Dialysis machine | |
| EP0228160B1 (en) | Apparatus for the filtration of plasma from blood | |
| JPH0244759Y2 (en) | ||
| JPS62142567A (en) | Double filtering type blood treatment apparatus | |
| JPH059008Y2 (en) | ||
| JPH0225407Y2 (en) | ||
| JPH0244760Y2 (en) | ||
| JPH06114102A (en) | Blood dialysis and filtration device | |
| JPH0651057B2 (en) | Blood processing equipment | |
| JPH0446756Y2 (en) | ||
| JPS6040303B2 (en) | Double filtration plasma exchanger | |
| JPH0117703B2 (en) | ||
| JPH0244761Y2 (en) | ||
| JPS62137061A (en) | Double filtering type blood treatment apparatus | |
| JPH0228982B2 (en) | ||
| JPS63292964A (en) | Plasma treatment apparatus | |
| JPS62254766A (en) | Serum separator | |
| JPS6327024B2 (en) | ||
| JPH0514589B2 (en) | ||
| CN111514396A (en) | Double-vein kettle external circulation system capable of automatically adjusting treatment dosage | |
| JPH0550304B2 (en) | ||
| JPH0228983B2 (en) |